LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Search

Gilead Sciences Inc.

Fechado

SetorSaúde

118.38 -0.55

Visão Geral

Variação de preço das ações

24h

Atual

Mín

118.26

Máximo

118.65

Indicadores-chave

By Trading Economics

Rendimento

645M

2B

Vendas

414M

7.1B

P/E

Médio do Setor

23.903

34.427

Rendimento de Dividendos

2.61

Margem de lucro

27.68

Funcionários

17,600

EBITDA

769M

3.4B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+4.64% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

2.61%

2.47%

Próxima data de dividendos

29 de set. de 2025

Próxima data de ex-dividendo

15 de set. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

7B

149B

Abertura anterior

118.93

Fecho anterior

118.38

Sentimento de Notícias

By Acuity

18%

82%

25 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Gilead Sciences Inc. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de ago. de 2025, 20:59 UTC

Ganhos

Gilead Sciences Upgrades Guidance After 2Q Results Top Views

24 de abr. de 2025, 20:17 UTC

Ganhos

Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance

8 de ago. de 2025, 20:28 UTC

Ganhos

These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More -- Barrons.com

8 de ago. de 2025, 17:27 UTC

Ganhos

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Microchip, and More -- Barrons.com

8 de ago. de 2025, 12:03 UTC

Ganhos

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Firefly -- Barrons.com

8 de ago. de 2025, 11:13 UTC

Ganhos

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Firefly -- Barrons.com

7 de ago. de 2025, 21:13 UTC

Ganhos

Gilead Earnings Beat Estimates, But All Eyes Are On New HIV Shot -- Barrons.com

7 de ago. de 2025, 20:44 UTC

Ganhos

Gilead Sciences Ups Guidance After 2Q Results Top Views

7 de ago. de 2025, 20:26 UTC

Ganhos

Gilead Sciences: Liver Disease Portfolio Sales Decreased 4% to $795M in 2Q >GILD

7 de ago. de 2025, 20:26 UTC

Ganhos

Gilead Sciences: 2Q Descovy Sales Increased 35% to $653M >GILD

7 de ago. de 2025, 20:25 UTC

Ganhos

Gilead Sciences: HIV Pdt Sales Increased 7% to $5.1 B in 2Q >GILD

7 de ago. de 2025, 20:24 UTC

Ganhos

Gilead Sciences: 2Q Biktarvy Sales Increased 9% Yr-Over-Yr to $3.5 B >GILD

7 de ago. de 2025, 20:22 UTC

Ganhos

Gilead Sciences 2Q Adj EPS $2.01 >GILD

7 de ago. de 2025, 20:22 UTC

Ganhos

Gilead Sciences 2Q Net $1.96B >GILD

7 de ago. de 2025, 20:22 UTC

Ganhos

Gilead Sciences Sees FY EPS $5.85-EPS $6.15 >GILD

7 de ago. de 2025, 20:22 UTC

Ganhos

Gilead Sciences 2Q Rev $7.1B >GILD

7 de ago. de 2025, 20:22 UTC

Ganhos

Gilead Sciences 2Q Total Liver Disease Sales $211M >GILD

7 de ago. de 2025, 20:22 UTC

Ganhos

Gilead Sciences Sees FY Adj EPS $7.95-Adj EPS $8.25 >GILD

7 de ago. de 2025, 20:22 UTC

Ganhos

Gilead Sciences 2Q EPS $1.56 >GILD

27 de abr. de 2025, 11:00 UTC

Principais Notícias

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

24 de abr. de 2025, 20:08 UTC

Ganhos

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences: As of March 31, 2025, $7.9 Billion of Cash and Cash Equivalents Compared to $10.0 Billion as of Dec. 31, 2024 >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences 1Q Rev $6.67B >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences: 1Q Product Gross Margin Was 76.7% Compared to 76.6% in Same Period in 2024 >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences: During 1Q Generated $1.8 Billion in Operating Cash Flow >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences: 1Q Lower Veklury (Remdesivir) and Oncology Sales Offset by Higher HIV and Liver Disease Sales >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences Sees 2025 EPS $5.65-EPS $6.05 >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences 1Q EPS $1.04 >GILD

Comparação entre Pares

Variação de preço

Gilead Sciences Inc. Previsão

Preço-alvo

By TipRanks

4.64% parte superior

Previsão para 12 meses

Média 123.86 USD  4.64%

Máximo 143 USD

Mínimo 98 USD

Com base em 24 analistas de Wall Street que oferecem metas de preço de 12 meses para Gilead Sciences Inc. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

24 ratings

18

Comprar

6

Manter

0

Vender

Pontuação Técnica

By Trading Central

97.33 / 103.17Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Very Strong Bearish Evidence

Longo Prazo

Weak Bullish Evidence

Sentimento

By Acuity

25 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.